|
1
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Airley RE and Mobasheri A: Hypoxic
regulation of glucose transport, anaerobic metabolism and
angiogenesis in cancer: novel pathways and targets for anticancer
therapeutics. Chemotherapy. 53:233–256. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Macheda ML, Rogers S and Best JD:
Molecular and cellular regulation of glucose transporter (GLUT)
proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Witte D, Ali N, Carlson N and Younes M:
Overexpression of the neutral amino acid transporter ASCT2 in human
colorectal adenocarcinoma. Anticancer Res. 22:2555–2557.
2002.PubMed/NCBI
|
|
6
|
Li R, Younes M, Frolov A, Wheeler TM,
Scardino P, Ohori M and Ayala G: Expression of neutral amino acid
transporter ASCT2 in human prostate. Anticancer Res. 23:3413–3418.
2003.PubMed/NCBI
|
|
7
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ganapathy V, Thangaraju M and Prasad PD:
Nutrient transporters in cancer: relevance to Warburg hypothesis
and beyond. Pharmacol Ther. 121:29–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanai Y, Segawa H, Miyamoto K, Uchino H,
Takeda E and Endou H: Expression cloning and characterization of a
transporter for large neutral amino acids activated by the heavy
chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yanagida O, Kanai Y, Chairoungdua A, et
al: Human L-type amino acid transporter 1 (LAT1): characterization
of function and expression in tumor cell lines. Biochim Biophys
Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oda K, Hosoda N, Endo H, et al: L-type
amino acid transporter 1 inhibitors inhibit tumor cell growth.
Cancer Sci. 101:173–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ichinoe M, Mikami T, Yoshida T, et al:
High expression of L-type amino-acid transporter 1 (LAT1) in
gastric carcinomas: comparison with non-cancerous lesions. Pathol
Int. 61:281–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nii T, Segawa H, Taketani Y, et al:
Molecular events involved in up-regulating human
Na+-independent neutral amino acid transporter LAT1
during T-cell activation. Biochem J. 358:693–604. 2001.PubMed/NCBI
|
|
14
|
Blackwell TK, Kretzner L, Blackwood EM,
Eisenman RN and Weintraub H: Sequence-specific DNA binding by the
c-Myc protein. Science. 250:1149–1151. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alex R, Sözeri O, Meyer S and Dildrop R:
Determination of the DNA sequence recognized by the bHLH-zip domain
of the N-Myc protein. Nucleic Acids Res. 20:2257–2263. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakata T, Ferdous G, Tsuruta T, et al:
L-type amino-acid transporter 1 as a novel biomarker for high-grade
malignancy in prostate cancer. Pathol Int. 59:7–18. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaira K, Oriuchi N, Imai H, et al:
Prognostic significance of L-type amino acid transporter 1 (LAT1)
and 4F2 heavy chain (CD98) expression in early stage squamous cell
carcinoma of the lung. Cancer Sci. 100:248–254. 2009. View Article : Google Scholar
|
|
18
|
Kaji M, Kabir-Salmani M, Anzai N, et al:
Properties of L-type amino acid transporter 1 in epidermal ovarian
cancer. Int J Gynecol Cancer. 20:329–336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bouchard C, Thieke K, Maier A, et al:
Direct induction of cyclin D2 by Myc contributes to cell cycle
progression and sequestration of p27. EMBO J. 18:5321–5333. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bouchard C, Dittrich O, Kiermaier A,
Dohmann K, Menkel A, Eilers M and Lüscher B: Regulation of cyclin
D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP
recruitment and histone acetylation at the cyclin D2 promoter.
Genes Dev. 15:2042–2047. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Menssen A and Hermeking H:
Characterization of the c-Myc-regulated transcriptome by SAGE:
identification and analysis of c-Myc target genes. Proc Natl Acad
Sci USA. 99:6274–6279. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JW, Zeller KI, Wang Y, Jegga AG,
Aronow BJ, O’Donnell KA and Dang CV: Evaluation of myc E-box
phylogenetic footprints in glycolytic genes by chromatin
immunoprecipitation assays. Mol Cell Biol. 24:5923–5936. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Osthus RC, Shim H, Kim S, et al:
Deregulation of glucose transporter 1 and glycolytic gene
expression by c-Myc. J Biol Chem. 275:21797–21800. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O’Donnell KA, Wentzel EA, Zeller KI, Dang
CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1
expression. Nature. 435:839–843. 2005.PubMed/NCBI
|
|
25
|
Frank SR, Schroeder M, Fernandez P,
Taubert S and Amati B: Binding of c-Myc to chromatin mediates
mitogen-induced acetylation of histone H4 and gene activation.
Genes Dev. 15:2069–2082. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Frank SR, Parisi T, Taubert S, et al: Myc
recruits the TIP60 histone acetyltransferase complex to chromatin.
EMBO Rep. 4:575–580. 2003. View Article : Google Scholar : PubMed/NCBI
|
